Healthcare provider profile · identity verified

Jamie L Skreen, DO

Family Practice · SALEM, OR · NPI 1083140115

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	327	135
Levothyroxine Sodium	Levothyroxine Sodium	259	101
Losartan Potassium	Losartan Potassium	233	101
Amlodipine Besylate	Amlodipine Besylate	227	96
Omeprazole	Omeprazole	174	77
Lisinopril	Lisinopril	143	66
Metformin Hcl Er	Metformin Hcl	134	60
Trazodone Hcl	Trazodone Hcl	118	51
Gabapentin	Gabapentin	100	47
Duloxetine Hcl	Duloxetine Hcl	96	43
Fluoxetine Hcl	Fluoxetine Hcl	84	28
Metformin Hcl	Metformin Hcl	74	34
Metoprolol Succinate	Metoprolol Succinate	74	37
Albuterol Sulfate Hfa	Albuterol Sulfate	70	40
Hydrochlorothiazide	Hydrochlorothiazide	67	38
Rosuvastatin Calcium	Rosuvastatin Calcium	63	29
Bupropion Xl	Bupropion Hcl	61	25
Eliquis	Apixaban	61	24
Furosemide	Furosemide	56	23
Tamsulosin Hcl	Tamsulosin Hcl	56	29
Clopidogrel	Clopidogrel Bisulfate	55	19
Famotidine	Famotidine	55	26
Sertraline Hcl	Sertraline Hcl	54	27
Fluticasone Propionate	Fluticasone Propionate	49	31
Jardiance	Empagliflozin	48	21
Ozempic	Semaglutide	48	19
Allopurinol	Allopurinol	45	18
Simvastatin	Simvastatin	42	26
Pantoprazole Sodium	Pantoprazole Sodium	41	23
Alendronate Sodium	Alendronate Sodium	40	22
Mirtazapine	Mirtazapine	39	suppressed
Atenolol	Atenolol	37	17
Escitalopram Oxalate	Escitalopram Oxalate	37	21
Potassium Chloride	Potassium Chloride	36	21
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	35	14
Montelukast Sodium	Montelukast Sodium	35	18
Pravastatin Sodium	Pravastatin Sodium	35	21
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	34	12
Memantine Hcl	Memantine Hcl	33	suppressed
Naproxen	Naproxen	32	16
Carvedilol	Carvedilol	31	13
Pregabalin	Pregabalin	30	14
Tramadol Hcl	Tramadol Hcl	30	11
Triamcinolone Acetonide	Triamcinolone Acetonide	30	24
Citalopram Hbr	Citalopram Hydrobromide	27	12
Cephalexin	Cephalexin	26	16
Glipizide Er	Glipizide	26	14
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	26	11
Hydroxyzine Hcl	Hydroxyzine Hcl	26	15
Metoprolol Tartrate	Metoprolol Tartrate	25	15
Meloxicam	Meloxicam	23	suppressed
Tizanidine Hcl	Tizanidine Hcl	23	suppressed
Donepezil Hcl	Donepezil Hcl	22	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	21	suppressed
Lovastatin	Lovastatin	21	suppressed
Trulicity	Dulaglutide	21	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	16
Azelastine Hcl	Azelastine Hcl	19	12
Chlorthalidone	Chlorthalidone	19	12
Finasteride	Finasteride	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	19	suppressed
Mounjaro	Tirzepatide	18	suppressed
Olanzapine	Olanzapine	18	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Ketoconazole	Ketoconazole	17	13
Rizatriptan	Rizatriptan Benzoate	16	suppressed
Ropinirole Hcl	Ropinirole Hcl	16	suppressed
Estradiol	Estradiol	15	11
Ezetimibe	Ezetimibe	15	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	15	15
Ventolin Hfa	Albuterol Sulfate	15	suppressed
Celecoxib	Celecoxib	14	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Nystatin	Nystatin	13	suppressed
Prednisone	Prednisone	13	11
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	12	suppressed
Mupirocin	Mupirocin	12	11
Premarin	Estrogens, Conjugated	12	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Lorazepam	Lorazepam	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Rybelsus	Semaglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error